OBJECTIVES: To assess treatment satisfaction between patients with self-reported asthma for two classes of asthma treatments, leukotriene modifiers (LM group) and inhaled corticosteroids (IC group), using a novel patient community in the U.S. METHODS: Participants were identified via MediGuard, a digital patient platform where patients enroll online to be part of a digital patient community.  All information was obtained through participant self-report. Patients were invited to complete the Treatment Satisfaction Questionnaire for Medication (TSQM), a patient reported outcome (PRO) instrument, at random time points between 2009 and 2011. Domain scores of the TSQM were compared between the IC and LM groups using regression analyses, adjusting for age, gender, self-reported severity and number of co-medications. RESULTS: 736 patients were included for the IC group, and 647 for LM group.  Average ages were comparable (56.3 years (SD=13.8) for IC; 54.9 (13.5) for LM).  Both groups were predominantly female (76.3% IC; 83.2%, LM).  Effectiveness domain scores were similar between IC and LM groups (p=0.502).  LM users reported significantly higher scores (i.e., increased satisfaction) for other domains: side effects (97.1 (SD=0.8) vs. 93.5 (0.7), resp.); convenience (89.2 (0.8) vs. 81.6 (0.7), resp.); global satisfaction (72.3 (1.1) vs. 67.3 (1.0).  CONCLUSIONS: Patients in the LM group reported higher satisfaction in the convenience and global satisfaction domains than the IC group. Patients in the LM group reported less interference with side effects than the IC group. Providing patients with information on population-based satisfaction scores for these two medications could help inform patients’ treatment selection decisions.